Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Sanja Sever
Massachusetts General Hospital, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
Trisaq, Inc.
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Dr. Sever is a co-founder of Trisaq, a company focused on develop novel dynamin-targeting drugs to treat kidney diseases. The company is generating a column to remove soluble urokinase-type plasminogen activator receptor (suPAR) from the patients with focal segmental glomerulosclerosis (FSGS) and the company is also screening for dynamin-specific small molecules to be used in the kidney diseases. In addition, Dr. Sever is an inventor on a patent related to targeting dynamin oligomerization in kidney diseases and the IP has been licensed to Trisaq. If successful, the results of the research could potentially affect the value of the company. Based on the magnitude of Dr. Sever’s financial interest in Trisaq and the close connection between the company’s interests and the research, the Partners Committee on Outside Activities (COA) review panel determined that the financial interest could directly and significantly affect the design, conduct, or reporting of the research.
Role of dynamin oligomerization in podocyte structure and function
In the United States alone, glomerular kidney diseases affects some 20 million people, and this number has roughly doubled within the last two decades. We have recently shown that a small molecule (drug) that specifically targets the GTPase dynamin restored podocyte structure and function and thus ameliorated proteinuria in diverse animal models of chronic kidney diseases. While we originally focused on the effects of this small molecule on the global organization of the actin cytoskeleton, here we propose to study its effects on actin-dependent clathrin-mediated endocytosis in podocytes.
Filed on September 02, 2016.
Tell us what you know about Sanja Sever's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Sanja Sever filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Sanja Sever | Massachusetts General Hospital | Conflict of Interest | Trisaq, Inc. | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.